



FEP Medical Policy Manual

FEP 7.01.153 Adipose-Derived Stem Cells in Autologous Fat Grafting to the Breast

Annual Effective Policy Date: April 1, 2026

Original Policy Date: March 2018

Related Policies:

None

Adipose-Derived Stem Cells in Autologous Fat Grafting to the Breast

Description

Description

Following a mastectomy, patients often experience pain and irradiated skin; as an adjunct to reconstructive breast surgery, surgeons will sometimes graft autologous fat to the breast. Adipose-derived stem cells (ADSCs) have been proposed as a supplement to the fat graft in an attempt to improve graft survival; however, whether ADSCs play a role in tumorigenesis is still relatively unknown.

OBJECTIVE

The objective of this evidence review is to determine whether autologous fat grafting to the breast with adipose-derived stem cell enrichment improves the net health outcome in individuals who have breast cancer and are undergoing reconstructive surgery.

POLICY STATEMENT

The use of adipose-derived stem cells in autologous fat grafting to the breast is considered **investigational**.

POLICY GUIDELINES

None

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

Reconstructive: In this document, procedures are considered reconstructive when intended to address a significant variation from normal related to accidental injury, disease, trauma, treatment of a disease, or congenital defect.

FDA REGULATORY STATUS

In September 2006, Celution Cell Concentration System (Cytori Therapeutics; San Diego, CA) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process as a cell saver device. The system is cleared for the collection, concentration, washing, and reinfusion of a patient's cells for applications that may include, but are not limited to, cardiovascular, plastic and reconstructive, orthopedic, vascular, and urologic surgeries and procedures. In 2007, Cytori Therapeutics received the FDA 510(k) clearance to market the Autologous Fat Transfer system, which transfers a patient's own adipose tissue from one part of the patient's body to another.

FDA product code: CAC.

RATIONALE

Summary of Evidence

For individuals who have breast cancer who receive autologous fat grafting to the breast with adipose-derived stem cells (ADSC) enrichment of the graft, the evidence includes small single-arm studies, some of which are prospective. Relevant outcomes are symptoms, morbid events, functional outcomes, quality of life, resource utilization, and treatment-related morbidity. The observational studies were heterogeneous in the patient selection, methods in harvesting stem cells, number of procedures, and outcomes measured. Studies have mainly reported patient and investigator satisfaction and functional and cosmetic results. One small, prospective study found that the use of ADSC enrichment with autologous fat grafting over autologous fat grafting alone improved the retention rate of the fat graft postoperatively at 6 and 12 months. Larger clinical trials are needed to confirm this benefit. Limitations of the data include sample sizes, short-term follow-up, and uncertainty about the possible oncologic influence ADSC may have on the fat grafting procedure. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Society for Aesthetic Plastic Surgery and American Society of Plastic Surgeons

In 2011, the American Society for Aesthetic Plastic Surgery and the American Society of Plastic Surgeons released a joint position statement on the use of stem cells in aesthetic surgery.⁹ Based on a systematic review of the peer-reviewed literature, the Societies concluded that while there is potential for the future use of stem cells in aesthetic surgical procedures, **the scientific evidence and other data are very limited in terms of assessing the safety or efficacy of stem cell therapies in aesthetic medicine.**

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES

1. Mizuno H, Hyakusoku H. Fat grafting to the breast and adipose-derived stem cells: recent scientific consensus and controversy. *Aesthet Surg J*. 2010; 30(3): 381-7. PMID 20601560
2. Wilson A, Butler PE, Seifalian AM. Adipose-derived stem cells for clinical applications: a review. *Cell Prolif*. Feb 2011; 44(1): 86-98. PMID 21199013
3. Sterodimas A, de Faria J, Nicaretta B, et al. Tissue engineering with adipose-derived stem cells (ADSCs): current and future applications. *J Plast Reconstr Aesthet Surg*. Nov 2010; 63(11): 1886-92. PMID 19969517
4. Yoshimura K, Sato K, Aoi N, et al. Cell-assisted lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived stem/stromal cells. *Aesthetic Plast Surg*. Jan 2008; 32(1): 48-55; discussion 56-7. PMID 17763894
5. Agha RA, Pidgeon TE, Borrelli MR, et al. Validated Outcomes in the Grafting of Autologous Fat to the Breast: The VOGUE Study. Development of a Core Outcome Set for Research and Audit. *Plast Reconstr Surg*. May 2018; 141(5): 633e-638e. PMID 29697603
6. Rigotti G, Marchi A, Gali M, et al. Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: a healing process mediated by adipose-derived adult stem cells. *Plast Reconstr Surg*. Apr 15 2007; 119(5): 1409-1422. PMID 17415234
7. Prez-Cano R, Vranckx JJ, Lasso JM, et al. Prospective trial of adipose-derived regenerative cell (ADRC)-enriched fat grafting for partial mastectomy defects: the RESTORE-2 trial. *Eur J Surg Oncol*. May 2012; 38(5): 382-9. PMID 22425137
8. Jeon HJ, Choi DH, Lee JH, et al. A Prospective Study of the Efficacy of Cell-Assisted Lipotransfer with Stromal Vascular Fraction to Correct Contour Deformities of the Autologous Reconstructed Breast. *Aesthetic Plast Surg*. Jun 2021; 45(3): 853-863. PMID 32995982
9. Kamakura T, Ito K. Autologous cell-enriched fat grafting for breast augmentation. *Aesthetic Plast Surg*. Dec 2011; 35(6): 1022-30. PMID 21533662

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
March 2018	New policy	The use of adipose-derived stem cells in autologous fat grafting to the breast is considered investigational.
March 2019	Replace policy	Policy updated with literature review through October 30, 2018; reference 5 added. Policy statement unchanged.
March 2020	Replace policy	Policy updated with literature review through December 4, 2019; no references added. Policy statement unchanged.
March 2021	Replace policy	Policy updated with literature review through November 13, 2020; no references added. Policy statement unchanged.
March 2022	Replace policy	Policy updated with literature review through November 19, 2021; reference added. Policy statement unchanged.
March 2023	Replace policy	Policy updated with literature review through November 11, 2022; no reference added. Policy statement unchanged.
March 2024	Replace policy	Policy updated with literature review through November 28, 2023; no references added. Policy statement unchanged.
March 2025	Replace policy	Policy updated with literature review through December 6, 2024; no references added. Policy statements unchanged.
March 2026	Replace policy	Policy updated with literature review through November 20, 2025; no references added. Policy statements unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.